The 5‐year PFS for the individual groups was as follows: PTCL‐NOS: 18.4%; AITL: 23.6%; ALK‐positive ALCL: 50.0%; ALK‐negative ALCL: 36.4%; and EATL: 0% (Figure 2A). The gene discussed is ALK; the disease is angioimmunoblastic T-cell lymphoma.